Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 5q cytogenetic abnormality, as part...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoeconomics
Main Authors: Blommestein, Hedwig M., Armstrong, Nigel, Ryder, Steve, Deshpande, Sohan, Worthy, Gill, Noake, Caro, Riemsma, Rob, Kleijnen, Jos, Severens, Johan L., Al, Maiwenn J.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2015
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4706836/
https://ncbi.nlm.nih.gov/pubmed/26314282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0318-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados